News

Filter by:
By year:
Reset
  • Press Release
  • Usher 1B

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
  • Press Release

AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
  • Press Release
  • Other

AAVantgarde Closes $141 Million Series B Financing
  • Publication

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today

  • Press Release
  • Stargardt

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
  • Press Release
  • Stargardt

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
  • Press Release
  • Usher 1B

AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
  • Press Release
  • Usher 1B

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
  • Press Release
  • Stargardt

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
  • Press Release
  • Stargardt

AAVantgarde Receives FDA IND Clearance to Progress Stargardt Disease program AAVB-039
  • Press Release
  • Usher 1B

AAVantgarde presents updated data of Usher 1B and STGD programs at ARVO 2025
  • Press Release

Rasmus Holm-Jorgensen appointed CFO at AAVantgarde
  • Press Release
  • Stargardt

AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
  • Publication
  • Stargardt

Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models

  • Press Release
  • Usher 1B

AAVantgarde announces 2 presentations at ARVO 2025